Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream
- 1 May 2005
- journal article
- case report
- Published by Wiley in International Journal of Dermatology
- Vol. 44 (5) , 428-434
- https://doi.org/10.1111/j.1365-4632.2005.02582.x
Abstract
Current treatment recommendations for malignant melanoma in situ include surgical excision with at least 0.5 cm margins. On the head or neck, obtaining adequate surgical margins for melanoma can be challenging and often disfiguring. In addition, some elderly patients may not be good surgical candidates and may request less aggressive interventions. We report herein three cases of malignant melanoma in situ on the face treated with topical imiquimod cream. Complete regression of malignant melanoma in situ was observed on treatment with 5% topical imiquimod cream. The varied treatment regimens, rationale for using imiquimod rather than performing surgery, and the possible mechanisms of action are discussed. Topical imiquimod can be used successfully for the treatment of malignant melanoma in situ on the face.Keywords
This publication has 16 references indexed in Scilit:
- Treatment of lentigo maligna with topical imiquimodBritish Journal of Dermatology, 2003
- Treatment of Melanoma In Situ on Sun-Damaged Skin With Topical 5% Imiquimod Cream Complicated by the Development of Invasive DiseaseArchives of Dermatology, 2003
- Extensive Lentigo Maligna Clearing With Topical ImiquimodArchives of Dermatology, 2003
- Histologic Resolution of Melanoma In Situ (Lentigo Maligna) With 5% Imiquimod CreamArchives of Dermatology, 2003
- Melanoma: Adjuvant therapy and other treatment optionsCurrent Treatment Options in Oncology, 2003
- The imidazoquinolines and their place in the therapy of cutaneous diseaseExpert Opinion on Pharmacotherapy, 2003
- Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathwayNature Immunology, 2002
- Surgical management of primary melanomaClinical and Experimental Dermatology, 2000
- Review Article Imiquimod applied topically: a novel immune response modifier and new class of drugInternational Journal of Immunopharmacology, 1999
- Self-administered Topical 5% Imiquimod Cream for External Anogenital WartsArchives of Dermatology, 1998